Cover Image
市場調查報告書

肝功能衰竭 : 開發中產品分析

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229798
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
肝功能衰竭 : 開發中產品分析 Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 80 Pages
簡介

肝功能衰竭,是指肝功能大幅度降低的狀態,由於各種肝疾病,肝臟大部分受到損傷時便發生肝功能衰竭。症狀為容易發生黃疸、瘀傷和出血 、腹水、腦功能障礙、不完全的體重增加、疲勞、四肢無力感、噁心、食慾不振等。因為這些症狀與其他各種條件有關係,要正確診斷可能要花費一定程度的時間。肝功能衰竭惡化,也可能喪失方向感和產生睡意。這個階段也有昏睡和死亡的危險性。治療方法依患者肝功能的運作情形不同而不同。

本報告提供肝功能衰竭的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

肝功能衰竭 概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alfact Innovation
  • BioLineRx Ltd
  • Cell2B Advanced Therapeutics SA
  • Conatus Pharmaceuticals Inc
  • Immune Pharmaceuticals Inc
  • Mina Therapeutics Ltd
  • Mylan NV
  • Ocera Therapeutics Inc
  • PledPharma AB
  • Promethera Biosciences SA
  • Silence Therapeutics Plc
  • Unicyte AG
  • Ventria Bioscience
  • Vital Therapies Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9971IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 2, 1, 7, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Liver Failure (Hepatic Insufficiency) - Overview
  • Liver Failure (Hepatic Insufficiency) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
  • BioLineRx Ltd
  • Cell2B Advanced Therapeutics SA
  • Genentech Inc
  • Immune Pharmaceuticals Inc
  • Mina Therapeutics Ltd
  • Mylan NV
  • Novartis AG
  • Ocera Therapeutics Inc
  • PledPharma AB
  • Promethera Biosciences SA
  • Therapure Biopharma Inc
  • Unicyte AG
  • Versantis AG
  • Vital Therapies Inc
  • Liver Failure (Hepatic Insufficiency) - Drug Profiles
  • albumin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BL-1220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • F-573 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HepaStem - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ImmuneSafe - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ipatasertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MTL-CEBPA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotide for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ornithine phenylacetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • silibinin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP3A4 for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VS-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XEN-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Liver Failure (Hepatic Insufficiency) - Dormant Projects
  • Liver Failure (Hepatic Insufficiency) - Discontinued Products
  • Liver Failure (Hepatic Insufficiency) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference
  • Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
  • Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group
  • Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
  • Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
  • Jun 08, 2017: First patient included in PledPharma's clinical trial with Aladote
  • Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
  • Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
  • May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure
  • Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid
  • Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01
  • Dec 31, 2015: Positive in vivo efficacy and safety results pave the way for the regulatory preclinical studies
  • Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
  • Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
  • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Novartis AG, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Therapure Biopharma Inc, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Versantis AG, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2017
  • Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top